Minneapolis-based Vital Images has recruited eight accredited institutional investors to purchase 1.5 million shares of common stock at $13.50 per share. The private placement, announced June 2, generated some $19 million after deducting closing costs
Minneapolis-based Vital Images has recruited eight accredited institutional investors to purchase 1.5 million shares of common stock at $13.50 per share. The private placement, announced June 2, generated some $19 million after deducting closing costs and placement fees. U.S. Bancorp Piper Jaffray served as exclusive placement agent for the transaction. Funds will provide the flexibility to expand VI's business through acquisition or other opportunities, according to the company. In weeks prior to the placement, VI stock soared to nearly $18. As of June 5, share price had settled at about $14.
FDA Approves Fluorescence Imaging System for Detecting Residual Breast Cancer
April 18th 2024The combination of the optical imaging agent Lumisight and the fluorescence imaging device Lumicell Direct Visualization System, collectively known as LumiSystem, reportedly offers 84 percent accuracy with real-time detection of residual breast cancer after lumpectomy procedures.
Study of Ofatumumab for Multiple Sclerosis Shows 'Profoundly Suppressed MRI Lesion Activity'
April 17th 2024The use of continuous ofatumumab in patients within three years of a relapsing multiple sclerosis diagnosis led to substantial reductions in associated lesions on brain MRI scans, according to research recently presented at the American Academy of Neurology (AAN) conference.
Could a Deep Learning Model for Mammography Improve Prediction of DCIS and Invasive Breast Cancer?
April 15th 2024Artificial intelligence (AI) assessment of mammography images may significantly enhance the prediction of invasive breast cancer and ductal carcinoma in situ (DCIS) in women with breast cancer, according to new research presented at the Society for Breast Imaging (SBI) conference.